Mixed Response to Nivolumab Among Different Metastatic Sites in Patients With Metastatic Renal Cell Carcinoma: Incidence and Clinical Implications
International Journal of Urology · 2026-07 · 33 (7)
DOI: 10.1111/iju.70571 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Urology, online erschienen am 12.07.2026. Verfasst von Yudai Ishikawa und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Institute of Science Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Nivolumab, Kidney Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objective
Discordant responses to immune checkpoint inhibition (ICIs) may occur at different sites in metastatic renal cell carcinoma (mRCC). This study investigated the incidence and prognostic significance of mixed response in mRCC patients treated with nivolumab.
Methods
We retrospectively analyzed 116 mRCC patients who underwent nivolumab monotherapy without prior ICIs. The best overall response (BOR) was evaluated for each patient using RECIST version 1.1, and organ‐specific responses were assessed for each metastatic site. Patients were classified into three groups: responders (lesion shrinkage in one or more metastatic organs without growth in any organ), non‐responders (no lesion shrinkage in any organ), and mixed responders (co‐existence of metastatic organ with shrinking lesions and those with growing lesions).
Results
The median age was 68 years, and 74.1% of patients were male. The IMDC risk was favorable/intermediate/poor in 17/79/20 patients, respectively. BOR was CR/PR/SD/PD in 2/24/38/52 patients, respectively; objective response rate (ORR) was 22.4%. In organ‐specific responses, ORR was lower for bone (7.1%), kidney (8.8%), and brain (0%) metastases than for other sites (17.4%–50.0%). The analysis classified 49 (42.2%), 15 (12.9%), and 52 (44.8%) patients as responders, mixed responders, and non‐responders, respectively. During a median follow‐up of 20.9 months, the median overall survival (OS) was 45.7 months. Two‐year OS rate was 72.7% overall, and 92.2%, 90.0%, and 46.4% for responders, mixed responders, and non‐responders, respectively ( p < 0.001).
Conclusions
Nivolumab yielded diverse organ‐specific responses, with 12.9% of patients exhibiting mixed response. Further studies are required to explore optimal management of mixed responders to immune checkpoint inhibition in mRCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Institute of Science Tokyo, Tokyo, Japan.
- Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
- Department of Urology, Saitama Cancer Center, Saitama, Japan.
ORCID-Profile: Yudai Ishikawa, Hajime Tanaka, Yoshitomo Yamaguchi, Riko Maruyama, Soichiro Yoshida
Zitieren
APA
Ishikawa, Y., Tanaka, H., Yamaguchi, Y., Maruyama, R., Fukuda, S., Waseda, Y., Inoue, M., Yoshida, S., Matsuoka, Y., Numao, N., & Fujii, Y. (2026). Mixed Response to Nivolumab Among Different Metastatic Sites in Patients With Metastatic Renal Cell Carcinoma: Incidence and Clinical Implications. International Journal of Urology, 33(7). https://doi.org/10.1111/iju.70571
Vancouver
Ishikawa Y, Tanaka H, Yamaguchi Y, Maruyama R, Fukuda S, Waseda Y, et al. Mixed Response to Nivolumab Among Different Metastatic Sites in Patients With Metastatic Renal Cell Carcinoma: Incidence and Clinical Implications. International Journal of Urology. 2026;33(7). doi:10.1111/iju.70571
BibTeX
@article{Ishikawa2026,
author = {Ishikawa, Yudai and Tanaka, Hajime and Yamaguchi, Yoshitomo and Maruyama, Riko and Fukuda, Shohei and Waseda, Yuma and Inoue, Masaharu and Yoshida, Soichiro and Matsuoka, Yoh and Numao, Noboru and Fujii, Yasuhisa},
title = {Mixed Response to Nivolumab Among Different Metastatic Sites in Patients With Metastatic Renal Cell Carcinoma: Incidence and Clinical Implications},
journal = {International Journal of Urology},
year = {2026},
volume = {33},
number = {7},
doi = {10.1111/iju.70571}
}
EUVIMED